Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.

Grinnell SG, Majumdar S, Narayan A, Le Rouzic V, Ansonoff M, Pintar JE, Pasternak GW.

J Pharmacol Exp Ther. 2014 Sep;350(3):710-8. doi: 10.1124/jpet.114.213199. Epub 2014 Jun 26.

PMID:
24970924
2.

Mediation of opioid analgesia by a truncated 6-transmembrane GPCR.

Lu Z, Xu J, Rossi GC, Majumdar S, Pasternak GW, Pan YX.

J Clin Invest. 2015 Jul 1;125(7):2626-30. doi: 10.1172/JCI81070. Epub 2015 May 26.

PMID:
26011641
3.

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, Pintar J, Pan YX, Pasternak GW.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19778-83. doi: 10.1073/pnas.1115231108. Epub 2011 Nov 21.

4.

Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene.

Wieskopf JS, Pan YX, Marcovitz J, Tuttle AH, Majumdar S, Pidakala J, Pasternak GW, Mogil JS.

Pain. 2014 Oct;155(10):2063-70. doi: 10.1016/j.pain.2014.07.014. Epub 2014 Aug 2.

PMID:
25093831
5.

Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.

Majumdar S, Subrath J, Le Rouzic V, Polikar L, Burgman M, Nagakura K, Ocampo J, Haselton N, Pasternak AR, Grinnell S, Pan YX, Pasternak GW.

J Med Chem. 2012 Jul 26;55(14):6352-62. doi: 10.1021/jm300305c. Epub 2012 Jul 16.

6.

Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions.

Pan YX, Xu J, Xu M, Rossi GC, Matulonis JE, Pasternak GW.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4917-22. doi: 10.1073/pnas.0811586106. Epub 2009 Mar 9.

7.

JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.

Codd EE, Carson JR, Colburn RW, Stone DJ, Van Besien CR, Zhang SP, Wade PR, Gallantine EL, Meert TF, Molino L, Pullan S, Razler CM, Dax SL, Flores CM.

J Pharmacol Exp Ther. 2009 Apr;329(1):241-51. doi: 10.1124/jpet.108.146969. Epub 2009 Jan 16.

8.
9.

Pain-facilitating medullary neurons contribute to opioid-induced respiratory depression.

Phillips RS, Cleary DR, Nalwalk JW, Arttamangkul S, Hough LB, Heinricher MM.

J Neurophysiol. 2012 Nov;108(9):2393-404. doi: 10.1152/jn.00563.2012. Epub 2012 Sep 5.

10.

Opioid peptide-derived analgesics.

Schiller PW.

AAPS J. 2005 Oct 14;7(3):E560-5. Review.

12.
13.

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.

Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J.

J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26.

14.
15.

CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone.

Brodsky M, Elliott K, Hynansky A, Inturrisi CE.

Brain Res Bull. 1995;38(2):135-41.

PMID:
7583338
16.

Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats.

Hashimoto T, Saito Y, Yamada K, Hara N, Kirihara Y, Tsuchiya M.

Anesthesiology. 2006 Sep;105(3):574-80.

PMID:
16931992
17.

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Daniels DJ, Lenard NR, Etienne CL, Law PY, Roerig SC, Portoghese PS.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19208-13. Epub 2005 Dec 19.

18.

Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.

Healy JR, Bezawada P, Shim J, Jones JW, Kane MA, MacKerell AD Jr, Coop A, Matsumoto RR.

ACS Chem Neurosci. 2013 Sep 18;4(9):1256-66. doi: 10.1021/cn4000428. Epub 2013 Jun 11.

19.

Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.

Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, Schröder W, Kögel BY, Beier H, Englberger W, Schunk S, De Vry J, Jahnel U, Frosch S.

J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. doi: 10.1124/jpet.114.213694. Epub 2014 Apr 8.

20.

Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.

Neilan CL, Nguyen TM, Schiller PW, Pasternak GW.

Eur J Pharmacol. 2001 May 4;419(1):15-23.

PMID:
11348625
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk